Replies to post #1026 on Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

Buyout offer would have probably been too low for management. As for why? The company indicated that Emricasan can be indicated for other liver disease and rare diseases. That means that the money it takes from the deal it can apply to other new pipeline drugs to enhance shareholder value. A buyout offer for Emricasan dealing with both NASH Fibrosis and NASH cirhossis would have been at least $3B which no pharma would pay for in only phase 2b of testing. Think about it TBRA only targets NASH fibrosis and not Cirhossis and was bought out for $1.7B

[fishhunter]

pgh, You answered your own question. Yes, YOU would be happy with $30 right now, but guess what.....the really great news is that the CEO of CNAT along with his entire team and BOD believe the company will be worth much much more than that relatively soon.

It is obvious that the only reason Novartis didn't buy them outright is because Conatus wouldn't let them! That is spectacular news for shareholders as it clearly tells us exactly where this is headed. It is a screaming long term buy. And long term isn't a decade or 5 years or even 3. The stock will head upward soon and keep going for a long time.

Happy New Year. My target is $24 one year from today. Just a pure guess.